Global Psoriasis Treatment Market [By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region – North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025]
INDUSTRY INSIGHTS
According to a new report by Rockville Research, the global psoriasis treatment market is estimated to be valued at US$ 27 billion in the year 2025, growing at a CAGR of 8.9% in the period 2019 to 2025. Growth of the market is driven by factors such as rising incidences of the autoimmune diseases, changing lifestyle, ageing population, increasing availability of biologics and biosimilars and growing awareness about the disease.
Psoriasis is a complex, chronic, inflammatory skin disorder that is characterized by itchy skin lesions. It involves hyperproliferation of the keratinocytes which leads to substantial increase in in the epidermal cell turnover rate.
Psoriasis therapeutics market is expected to witness substantial uptake of Biosimilars for currently marketed biologics. The market is expected to get slew of these novel products in the upcoming years. Currently, there are very few biosimilars approved for the treatment of psoriasis and psoriatic arthritis.
REPORT SCOPE
This report “Global Psoriasis Treatment Market [By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region – North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025]” provides a detailed analysis of the global psoriasis therapeutics market from qualitative and quantitative outlooks during the forecast period across various therapeutic classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Parameter Description
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global psoriasis therapeutics market report has been segmented on the basis of drug classes and region:-
Therapeutic Class Outlook, Revenue (2017 – 2025E, US$ Billions)
We provide customization of the study in order to provide specific information as sought by the client.
According to a new report by Rockville Research, the global psoriasis treatment market is estimated to be valued at US$ 27 billion in the year 2025, growing at a CAGR of 8.9% in the period 2019 to 2025. Growth of the market is driven by factors such as rising incidences of the autoimmune diseases, changing lifestyle, ageing population, increasing availability of biologics and biosimilars and growing awareness about the disease.
Psoriasis is a complex, chronic, inflammatory skin disorder that is characterized by itchy skin lesions. It involves hyperproliferation of the keratinocytes which leads to substantial increase in in the epidermal cell turnover rate.
Psoriasis therapeutics market is expected to witness substantial uptake of Biosimilars for currently marketed biologics. The market is expected to get slew of these novel products in the upcoming years. Currently, there are very few biosimilars approved for the treatment of psoriasis and psoriatic arthritis.
REPORT SCOPE
This report “Global Psoriasis Treatment Market [By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region – North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025]” provides a detailed analysis of the global psoriasis therapeutics market from qualitative and quantitative outlooks during the forecast period across various therapeutic classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Parameter Description
- Base year 2016
- Forecast period 2019 - 2025
- Market sizing Revenue in US$ Billions & CAGR for the period 2019 to 2025
- Country coverage The US, The UK, Germany & Japan
- Vendor scope AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly & Company, Inc.
- Report coverage Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global psoriasis therapeutics market report has been segmented on the basis of drug classes and region:-
Therapeutic Class Outlook, Revenue (2017 – 2025E, US$ Billions)
- Tumor necrosis factor-alpha (TNF-alpha) Inhibitors
- Interleukin (IL) Inhibitors
- T-cell Inhibitors
- North America
- Europe
- Asia Pacific
- The US
- The UK
- Germany
- Japan
- AbbVie Inc.
- Amgen Inc.
- Johnson & Johnson
- Novartis AG
- Eli Lilly & Company, Inc.
- Psoriasis Drug Manufacturers
- Chemical Suppliers
- End Users
- Research Professionals
- Healthcare Consultancies
- Regulatory Bodies
- Historical market size of migraine therapeutics from 2016 to 2018 in US$ Billions.
- Projected market growth in the forecasted period 2019 to 2025 with estimated revenue for each year in US$ Billions.
- Revenue forecasts of major psoriasis therapeutics in the period 2016 to 2025 in US$ Billions.
- Regional and country of migraine therapeutics in the period 2017 to 2025 in US$ Billions.
- Market drivers, restraints and industry trends that has impact on revenue.
- Profiling of major companies with detailed analysis of major psoriasis therapeutics approved for marketing as well as in pipeline.
We provide customization of the study in order to provide specific information as sought by the client.
1. EXECUTIVE SUMMARY
2. RESEARCH METHODOLOGY
3. PSORIASIS
3.1 Overview
3.1.1 Symptoms
3.1.2 Causes
3.2 Types
3.2.1 Plaque psoriasis
3.2.2 Guttate psoriasis
3.2.3 Pustular psoriasis
3.2.4 Inverse psoriasis
3.2.5 Erythrodermic psoriasis
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment
4. MARKET ANALYSIS
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Products
4.2.2 Market Share by Therapeutic Class
4.2.3 Market Share by Mode of Administration
4.2.4 Market Share by Region
5. DRUG ANALYSIS
5.1 Biologics
5.1.1 Tumor necrosis factor-alpha (TNF-alpha) Inhibitors
5.1.1.1 Overview
5.1.1.2 Market Sizing (Actual & Forecasted)
5.1.2 Interleukin (IL) Inhibitors
5.1.2.1 Overview
5.1.2.2 Market Sizing (Actual & Forecasted)
5.1.3 T-cell Inhibitors
5.1.3.1 Overview
5.1.3.2 Market Sizing (Actual & Forecasted)
6. REGIONAL ANALYSIS
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Therapeutic Class
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 The UK
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Germany
6.2.3.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 Japan
6.3.2.1 Market Sizing (Actual & Forecasted)
7. MARKET DYNAMICS
7.1 Industry Trends & Developments
7.1.1 Increasing Adoption of Interleukin (IL) Inhibitors
7.1.2 Uptake of Biosimilars
7.1.3 Patent Expirations
7.1.4 Mergers & Acquisitions
7.2 Growth Drivers
7.2.1 Rising Incidences of Autoimmune Diseases
7.2.2 Changing Lifestyle
7.2.3 Ageing Population
7.2.4 Increasing Availability of Biologics & Biosimilars
7.2.5 Growing Awareness
7.3 Challenges
7.3.1 Stringent Regulations
7.3.2 Side-effects of Oral Drugs
7.3.3 High Cost of Drugs
8. COMPETITIVE LANDSCAPE
8.1 Financial Analysis
8.2 Market Share Analysis
9. COMPANY PROFILES
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 Johnson & Johnson
9.4 Novartis AG
9.5 Eli Lilly & Company
2. RESEARCH METHODOLOGY
3. PSORIASIS
3.1 Overview
3.1.1 Symptoms
3.1.2 Causes
3.2 Types
3.2.1 Plaque psoriasis
3.2.2 Guttate psoriasis
3.2.3 Pustular psoriasis
3.2.4 Inverse psoriasis
3.2.5 Erythrodermic psoriasis
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment
4. MARKET ANALYSIS
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Products
4.2.2 Market Share by Therapeutic Class
4.2.3 Market Share by Mode of Administration
4.2.4 Market Share by Region
5. DRUG ANALYSIS
5.1 Biologics
5.1.1 Tumor necrosis factor-alpha (TNF-alpha) Inhibitors
5.1.1.1 Overview
5.1.1.2 Market Sizing (Actual & Forecasted)
5.1.2 Interleukin (IL) Inhibitors
5.1.2.1 Overview
5.1.2.2 Market Sizing (Actual & Forecasted)
5.1.3 T-cell Inhibitors
5.1.3.1 Overview
5.1.3.2 Market Sizing (Actual & Forecasted)
6. REGIONAL ANALYSIS
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Therapeutic Class
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 The UK
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Germany
6.2.3.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 Japan
6.3.2.1 Market Sizing (Actual & Forecasted)
7. MARKET DYNAMICS
7.1 Industry Trends & Developments
7.1.1 Increasing Adoption of Interleukin (IL) Inhibitors
7.1.2 Uptake of Biosimilars
7.1.3 Patent Expirations
7.1.4 Mergers & Acquisitions
7.2 Growth Drivers
7.2.1 Rising Incidences of Autoimmune Diseases
7.2.2 Changing Lifestyle
7.2.3 Ageing Population
7.2.4 Increasing Availability of Biologics & Biosimilars
7.2.5 Growing Awareness
7.3 Challenges
7.3.1 Stringent Regulations
7.3.2 Side-effects of Oral Drugs
7.3.3 High Cost of Drugs
8. COMPETITIVE LANDSCAPE
8.1 Financial Analysis
8.2 Market Share Analysis
9. COMPANY PROFILES
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 Johnson & Johnson
9.4 Novartis AG
9.5 Eli Lilly & Company
